Can Ozge, Erdemgil Yigit, Yildirim Zeynep Zulfiye, Ozduman Koray, Pamir M Necmettin, Sav Aydin, Ozpinar Aysel
Department of Medical Biochemistry, Acibadem Univeristy, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
Department of Neurosurgery, Acibadem Univeristy, Istanbul, Turkey Acibadem University Neuroscience Center - Brain Tumor Research Group, Acibadem University, Istanbul, Turkey.
Cancer Biomark. 2014;14(4):253-8. doi: 10.3233/CBM-140400.
DR-70 is an immunoassay for fibrin and FDP in plasma and it has been shown useful in detection of over 14 different cancers. This study investigated the validity of the DR-70 test in gliomas as well as meningiomas.
77 brain tumor patients as well as 40 healthy individuals were prospectively included in the study and investigated using DR-70 kit. The glioma cohort of 33 patients consisted of 1, 11, 6 and 15 WHO grade 1, 2, 3 and 4 gliomas, respectively. The meningioma cohort of 44 patients contained 38, 5 and 1 WHO grade 1, 2 and 3 tumors.
Test results were significantly higher than control values for both gliomas and meningiomas. The most balanced sensitivity and specificity values were obtained at cut-off level of 0.5 μg/ml FDP for both gliomas and meningiomas. Above this cutoff level the relative-risk for having a glioma was 5.1 times higher compared to controls with sensitivity and specificity of 76% and 85%, respectively. The relative-risk for meningioma was 5.8 with a sensitivity and specificity of 87% and 85%, respectively.
FDP testing, which is a nonspecific cancer screening tool, is sensitive to the two most common primary brain malignancies, gliomas and meningiomas.
DR - 70是一种用于检测血浆中纤维蛋白和纤维蛋白降解产物（FDP）的免疫测定法，已证明其在检测超过14种不同癌症方面具有实用性。本研究调查了DR - 70检测在胶质瘤和脑膜瘤中的有效性。
前瞻性纳入77例脑肿瘤患者和40例健康个体，使用DR - 70试剂盒进行检测。33例患者的胶质瘤队列分别包括1例、11例、6例和15例世界卫生组织（WHO）1级、2级、3级和4级胶质瘤。44例患者的脑膜瘤队列包含WHO 1级、2级和3级肿瘤分别为38例、5例和1例。
胶质瘤和脑膜瘤的检测结果均显著高于对照值。对于胶质瘤和脑膜瘤，在FDP截断水平为0.5μg/ml时获得了最平衡的敏感性和特异性值。高于此截断水平，患胶质瘤的相对风险比对照组高5.1倍，敏感性和特异性分别为76%和85%。脑膜瘤的相对风险为5.8，敏感性和特异性分别为87%和85%。
FDP检测作为一种非特异性癌症筛查工具，对两种最常见的原发性脑恶性肿瘤——胶质瘤和脑膜瘤具有敏感性。
